<p>Mankind Pharma on Tuesday said it has collaborated with South Korean firm Daewoong Pharmaceutical Co for conducting phase-I clinical trial of a novel formulation of Niclosamide for the treatment of Covid-19 patients in India.</p>.<p>The trial is designed towards addressing the need for an investigation on this new formulation based on encouraging preclinical evidence for the treatment of Covid-19, Mankind Pharma said in a statement. </p>.<p>"We are excited to collaborate with Daewoong Pharmaceutical Co Ltd to bring novel formulation of Niclosamide (DWRX2003) for the treatment of Covid-19 patients in India.</p>.<p>"We believe that the product would provide for a safe and effective alternative to patients suffering from this disease," Mankind Pharma COO Arjun Juneja said.</p>.<p>Both companies have received approval from the Drugs Controller General of India (DCGI) to conduct phase-1 clinical trials.</p>.<p>Daewoong Pharmaceutical CEO Sengho Jeon said, "Through development of candidates for Covid-19 treatments such as Nicosamide, which Daewoong Pharmaceutical is currently developing, we expect to provide innovative treatment option for patients suffering from Covid-19."</p>.<p>Mankind Pharma is one of the best partners to accelerate the clinical development and supply of DWRX2003 for India, he added. </p>
<p>Mankind Pharma on Tuesday said it has collaborated with South Korean firm Daewoong Pharmaceutical Co for conducting phase-I clinical trial of a novel formulation of Niclosamide for the treatment of Covid-19 patients in India.</p>.<p>The trial is designed towards addressing the need for an investigation on this new formulation based on encouraging preclinical evidence for the treatment of Covid-19, Mankind Pharma said in a statement. </p>.<p>"We are excited to collaborate with Daewoong Pharmaceutical Co Ltd to bring novel formulation of Niclosamide (DWRX2003) for the treatment of Covid-19 patients in India.</p>.<p>"We believe that the product would provide for a safe and effective alternative to patients suffering from this disease," Mankind Pharma COO Arjun Juneja said.</p>.<p>Both companies have received approval from the Drugs Controller General of India (DCGI) to conduct phase-1 clinical trials.</p>.<p>Daewoong Pharmaceutical CEO Sengho Jeon said, "Through development of candidates for Covid-19 treatments such as Nicosamide, which Daewoong Pharmaceutical is currently developing, we expect to provide innovative treatment option for patients suffering from Covid-19."</p>.<p>Mankind Pharma is one of the best partners to accelerate the clinical development and supply of DWRX2003 for India, he added. </p>